Serum-Free Medium Enhances the Immunosuppressive and Antifibrotic Abilities of Mesenchymal Stem Cells Utilized in Experimental Renal Fibrosis
Open Access
- 30 September 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 7 (12) , 893-905
Abstract
Serum used in culture medium brings risks of immune reactions or infections and thus may hinder using ex vivo expanded mesenchymal stem cells (MSCs) for medical treatment. Here, we cultured MSCs in a serum-free medium (SF-MSCs) and in a medium containing 10% fetal bovine serum (10%MSCs) and investigated their effects on inflammation and fibrosis. MSC-conditioned medium suppressed transforming growth factor-β1–induced phosphorylation of Smad2 in HK-2 cells, with no significant difference between the two MSCs. This finding suggests that the direct antifibrotic effect of SF-MSCs is similar to that of 10%MSCs. However, immunohistochemistry revealed that renal fibrosis induced by unilateral ureteral obstruction in rats was more significantly ameliorated by the administration of SF-MSCs than by that of 10%MSCs. Coculture of MSCs and monocytic THP-1 cell-derived macrophages using a Transwell system showed that SF-MSCs significantly induced polarization from the proinflammatory M1 to the immunosuppressive M2 phenotype macrophages, suggesting that SF-MSCs strongly suppress the persistence of inflammation. Furthermore, the gene expression of tumor necrosis factor-α–induced protein 6 (TSG-6), which inhibits the recruitment of inflammatory cells, was higher in SF-MSCs than in 10%MSCs, and TSG-6 knockdown in SF-MSCs attenuated the anti-inflammatory responses in unilateral ureteral obstruction rats. These findings imply that SF culture conditions can enhance the immunosuppressive and antifibrotic abilities of MSCs and the administration of ex vivo expanded SF-MSCs has the potential to be a useful therapy for preventing the progression of renal fibrosis. Stem Cells Translational Medicine 2018;7:893–905Keywords
Funding Information
- JSPS KAKENHI (JP17K09699, JP26461229)
This publication has 55 references indexed in Scilit:
- Resolvin D1 protects the liver from ischemia/reperfusion injury by enhancing M2 macrophage polarization and efferocytosisBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2016
- Human platelet lysate: Replacing fetal bovine serum as a gold standard for human cell propagation?Biomaterials, 2016
- Renoprotective Effect of Renin-Angiotensin-Aldosterone System Blockade in Patients With Predialysis Advanced Chronic Kidney Disease, Hypertension, and AnemiaJAMA Internal Medicine, 2014
- Isolation, expansion and characterization of bone marrow-derived mesenchymal stromal cells in serum-free conditionsCell and tissue research, 2014
- Concise Review: Two negative feedback loops place mesenchymal stem/stromal cells at the center of early regulators of inflammationStem Cells, 2013
- Immunosuppression effects of bone marrow mesenchymal stem cells on renal interstitial injury in rats with unilateral ureteral obstructionCellular Immunology, 2012
- Mesenchymal stem cells expanded in human platelet lysate display a decreased inhibitory capacity on T‐ and NK‐cell proliferation and functionEuropean Journal of Immunology, 2011
- Mesenchymal stem cell–educated macrophages: A novel type of alternatively activated macrophagesExperimental Hematology, 2009
- Increased proliferation of human synovial mesenchymal stem cells with autologous human serum: Comparisons with bone marrow mesenchymal stem cells and with fetal bovine serumArthritis & Rheumatism, 2008
- Human autologous serum obtained using a completely closed bag system as a substitute for foetal calf serum in human mesenchymal stem cell culturesCell Biology International, 2006